In the FIGHT trial on patients hospitalized for HFrEF, Liraglutide did not show benefit on time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels from baseline to 180 days [51]
While these average changes seem minimal, caution is warranted: if a patient has underlying high blood pressure or heart disease, even transient increases could be risky
In short: GHK-Cu is a science-backed powerhouse with real, measurable results
T1D Exchange and the author do not endorse the use of cannabis, are not medical professionals, and do not give medical advice
Headaches occur in a small percentage of users, likely related to the gut-brain axis response to microbiome changes